Vyripharm Enterprises
Houston, US · Founded 2014 · Delaware corporation
Founders & leadership
JB
Jerry BryantinExecutive
Reported raises · per SEC filings
Form D private placements$300M disclosed across 1 of 2 rounds · 2016–2021
▶$300MraisedOct 2021 · 2 investors · PharmaceuticalsRule 506(b)
▶$300MraisedOct 2021 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jerry BryantExecutive Officer, Director
- Offering amount
- $300M
- Amount sold
- $300M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$2.3MofferedAug 2016 · BiotechnologyRule 506(b)
▶$2.3MofferedAug 2016 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jerry BryantExecutive Officer, Director
- Offering amount
- $2.3M
- Minimum investment
- $50K
- Finders' fees
- $200K
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has Vyripharm Enterprises raised?
- Vyripharm Enterprises has disclosed $300M raised across 1 of its 2 known rounds.
- Where is Vyripharm Enterprises headquartered?
- Vyripharm Enterprises is headquartered in Houston, US.